This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...
The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its ...
Sanofi’s cancer drug pipeline has only one antibody drug conjugate, the last remnant of a nearly two decade-old research alliance that has not panned out as well as hoped. But ADCs have seen a ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...
SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...
GSK’s cancer drug pipeline is getting bigger with the addition of another antibody drug conjugate, or ADC. It’s the second time in as many months that GSK has turned to Hansoh Pharma for one of the ...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the ...
Solid tumors remain largely unresponsive to immune checkpoint inhibitors, in part due to their ability to suppress the cytotoxic activity of immune cells infiltrating the tumor microenvironment. One ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback